Mott Sarah L相关文献与解析，生知库 | 链接生命科学的每一步

Tran, Catherine G; Dornbush, Carine; Jensen, Braden S; Mott, Sarah L; Fannon, Elise E H; Stark, Austin C; Mali, Meghan E; Berg, Daniel J; Talbert, Erin E; Chan, Carlos H F

肿瘤

肠癌

肿瘤免疫

Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma.

高剂量硒代-L-蛋氨酸联合阿昔替尼治疗既往接受过治疗的转移性透明细胞肾细胞癌患者的 I 期临床试验

期刊:Clinical Cancer Research

影响因子:10.2

doi:10.1158/1078-0432.CCR-24-3234

Zakharia Yousef, Reis Ryan J, Kroll Matthew R, Rataan Aseel O, Manchkanti Srija, Rahim Bilal, Garje Rohan, Swami Umang, Mott Sarah L, Zamba K D, Sieren Jessica C, Salem Aliasger K, Rustum Youcef

细胞生物学

发表日期：2025

文献求助收藏

Assessing the efficacy and safety of sequential intravesical gemcitabine and docetaxel - does time from transurethral resection of bladder tumour to induction matter?

评估序贯膀胱内吉西他滨和多西他赛的疗效和安全性——从经尿道膀胱肿瘤切除术到诱导治疗的时间是否重要？

期刊:Bju International

影响因子:4.4

doi:10.1111/bju.16716

McElree, Ian M; Henning, Grant M; Steinberg, Ryan L; Hougen, Helen Y; Mott, Sarah L; O'Donnell, Michael A; Packiam, Vignesh T

The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC

高危非肌层浸润性膀胱癌诱导治疗后首次随访期间，蓝光膀胱镜检查及其他手术评估的作用。

期刊:Bladder Cancer

影响因子:1.2

doi:10.1177/23523735251324318

McElree, Ian M; Steinberg, Ryan L; Mott, Sarah L; Hougen, Helen Y; O'Donnell, Michael A; Packiam, Vignesh T

Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients

对于老年多发性骨髓瘤患者，采用硼替佐米、沙利度胺和美法仑进行移植预处理，并进行为期2年的移植后强化治疗。

期刊:Bone Marrow Transplantation

影响因子:5.2

doi:10.1038/s41409-023-02119-9

Strouse, Christopher; Mott, Sarah L; Smith, Brian J; Magalhaes-Silverman, Margarida; Farooq, Umar; Zhan, Fenghuang; Jethava, Yogesh; Tricot, Guido

Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017

一项针对既往接受过治疗的晚期非小细胞肺癌（NSCLC）患者的 Ib/II 期研究，评估 imprime PGG 和帕博利珠单抗的疗效：BTCRC LUN 15-017

期刊:Translational Lung Cancer Research

影响因子:3.5

doi:10.21037/tlcr-24-346

Furqan, Muhammad; Malhotra, Jyoti; Shergill, Ardaman; Liu, Li; Mott, Sarah L; Pasquinelli, Mary M; Hulbert, Alicia; Kennedy, Kathleen; Feldman, Lawrence

Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer

紫杉醇联合吉西他滨治疗复发/难治性小细胞肺癌的II期研究

期刊:Frontiers in Oncology

影响因子:3.3

doi:10.3389/fonc.2024.1303268

Byrne, Margaret M; Sutamtewagul, Grerk; Zeitler, William; Mott, Sarah L; Zamba, Gideon K D; Kojadinovic, Arsenije; Zhang, Jun; Abu-Hejleh, Taher; Clamon, Gerald; Furqan, Muhammad

Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma

序贯腔内吉西他滨和多西他赛治疗临床非侵袭性高级别上尿路尿路上皮癌

期刊:Urologic Oncology-Seminars and Original Investigations

影响因子:2.3

doi:10.1016/j.urolonc.2023.08.013

McElree, Ian M; Belzer, Alex; Mott, Sarah L; Packiam, Vignesh T; O'Donnell, Michael A; Steinberg, Ryan L

Longitudinal Outcomes of Malignant Ureteral Obstruction Secondary to Ovarian Cancer: Predictors of Resolution and the Role of Surgical Management

卵巢癌继发恶性输尿管梗阻的长期预后：梗阻缓解的预测因素及手术治疗的作用

期刊:Urology

影响因子:2

doi:10.1016/j.urology.2024.02.001

Faidley, Kathryn N; Botkin, Hannah E; Loeffler, Bradley T; Mott, Sarah L; Hansen, Samuel C; Hill, Emily K; Erickson, Bradley A

Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer

高危非肌层浸润性膀胱癌级联挽救治疗策略的长期疗效

Obesity, survival, and chemotherapy outcomes in stage IV colorectal cancer: a retrospective study

肥胖、生存率和IV期结直肠癌化疗结果：一项回顾性研究

Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma.

高剂量硒代-L-蛋氨酸联合阿昔替尼治疗既往接受过治疗的转移性透明细胞肾细胞癌患者的 I 期临床试验

Assessing the efficacy and safety of sequential intravesical gemcitabine and docetaxel - does time from transurethral resection of bladder tumour to induction matter?

评估序贯膀胱内吉西他滨和多西他赛的疗效和安全性——从经尿道膀胱肿瘤切除术到诱导治疗的时间是否重要？

The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC

高危非肌层浸润性膀胱癌诱导治疗后首次随访期间，蓝光膀胱镜检查及其他手术评估的作用。

Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients

对于老年多发性骨髓瘤患者，采用硼替佐米、沙利度胺和美法仑进行移植预处理，并进行为期2年的移植后强化治疗。

Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017

一项针对既往接受过治疗的晚期非小细胞肺癌（NSCLC）患者的 Ib/II 期研究，评估 imprime PGG 和帕博利珠单抗的疗效：BTCRC LUN 15-017

Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer

紫杉醇联合吉西他滨治疗复发/难治性小细胞肺癌的II期研究

Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma

序贯腔内吉西他滨和多西他赛治疗临床非侵袭性高级别上尿路尿路上皮癌

Longitudinal Outcomes of Malignant Ureteral Obstruction Secondary to Ovarian Cancer: Predictors of Resolution and the Role of Surgical Management

卵巢癌继发恶性输尿管梗阻的长期预后：梗阻缓解的预测因素及手术治疗的作用